Literature DB >> 15283899

Delivering prostate cancer prevention messages to the public: how the National Cancer Institute (NCI) effectively spread the word about the Prostate Cancer Prevention Trial (PCPT) results.

Kara Smigel Croker1, Anne Ryan, Thuy Morzenti, Lynn Cave, Tamara Maze-Gallman, Leslie Ford.   

Abstract

The Prostate Cancer Prevention Trial was the first clinical trial to show that a direct intervention (5 mg of finasteride daily for 7 years) could reduce a man's risk of developing prostate cancer. Initial results also suggested that men taking finasteride had an increased risk of developing what appeared to be higher-grade disease (Gleason score 7-10). The National Cancer Institute has a congressional mandate to communicate health information to the public and has established methods to reach the public directly and to reach information intermediaries in the media, professional societies, and advocacy groups. The groundbreaking yet complicated results of the Prostate Cancer Prevention Trial were widely disseminated by National Cancer Institute using the social marketing and public-relations strategies and tactics detailed here. Copyright 2004 Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15283899     DOI: 10.1016/j.urolonc.2004.04.015

Source DB:  PubMed          Journal:  Urol Oncol        ISSN: 1078-1439            Impact factor:   3.498


  2 in total

1.  Canadian Consensus Conference: The FDA decision on the use of 5ARIs.

Authors:  Laurence Klotz; Michael Chetner; Joseph Chin; Tony Finelli; Neil Fleshner; Yves Fradet; Larry Goldenberg; J Curtis Nickel; Robert Siemens; Alan So; Linda Sugar; Alexandre Zlotta; Eric Klein; Howard Parnes; David Penson
Journal:  Can Urol Assoc J       Date:  2012-04       Impact factor: 1.862

2.  Substantial utilization of Facebook, Twitter, YouTube, and Instagram in the prostate cancer community.

Authors:  J P Struck; F Siegel; M W Kramer; I Tsaur; A Heidenreich; A Haferkamp; A S Merseburger; J Salem; H Borgmann
Journal:  World J Urol       Date:  2018-03-09       Impact factor: 4.226

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.